[1]
|
《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究, 2021, 19(7): 582-590.
|
[2]
|
Feng, Y., Chen, L., Liu, Y., et al. (2020) Association between Apolipoprotein B XbaI Polymorphisms and Coronary Heart Disease: A Meta-Analysis. BMC Cardiovascular Disorders, 20, Article No. 265.
https://doi.org/10.1186/s12872-020-01545-7
|
[3]
|
Yu, D., Ma, L., Zhou, J., et al. (2020) Influence of Genotype on Antiplatelet Treatment Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Heart Disease. Experimental and Therapeutic Medicine, 19, 3411-3418.
https://doi.org/10.3892/etm.2020.8592
|
[4]
|
McPherson, R. and Tybjaerg-Hansen, A. (2016) Genetics of Coronary Artery Disease. Circulation Research, 118, 564-578. https://doi.org/10.1161/CIRCRESAHA.115.306566
|
[5]
|
纪昕, 岳晓乐, 赵丹丹, 等. 同型半胱氨酸与动脉粥样硬化患者血管内皮细胞损伤相关性[J]. 标记免疫分析与临床, 2017, 24(1): 73-76.
|
[6]
|
Yang, B., Liu, Y., Li, Y., et al. (2013) Geographical Distribution of MTHFR C677T, A1298C and MTRR A66G Gene Polymorphisms in China: Findings from 15357 Adults of Han Nationality. PLoS ONE, 8, e57917.
https://doi.org/10.1371/journal.pone.0057917
|
[7]
|
沈静, 张红琴, 马蔡昀, 等. MTHFR基因C667T和A1298C多态位点和高同型半胱氨酸与冠心病的相关性研究[J]. 标记免疫分析与临床, 2020, 27(2): 219-223+241.
|
[8]
|
陈宁, 孙婷, 陈明. MTHFR基因C677T多态性与冠状动脉支架植入术后再狭窄的相关性研究[J]. 中国循证心血管医学杂志, 2021, 13(6): 734-737.
|
[9]
|
李柳, 张晓婵, 茹琪, 等. 四氢叶酸还原酶基因多态性与冠心病严重程度的相关性[J]. 昆明医科大学学报, 2021, 42(5): 138-142.
|
[10]
|
马芳芳, 谢华斌. MTHFR基因C677T多态性与中国人群冠心病相关性的Meta分析[J]. 临床心血管病杂志, 2018, 34(10): 965-969.
|
[11]
|
Wu, K., Zhang, S., Guan, Z., et al. (2021) Methylenetetrahydrofolate Reductase Gene Polymorphism C677T Is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients. Chinese Medical Sciences Journal, 36, 103-109.
|
[12]
|
张晶, 丛洪良, 曹路, 等. 亚甲基四氢叶酸还原酶A1298C多态性与高同型半胱氨酸血症的相关性[J]. 中华老年心脑血管病杂志, 2017, 19(11): 1166-1169.
|
[13]
|
Saleheen, D., Zhao, W., Young, R., et al. (2017) Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions. Circulation, 135, 2336-2353.
|
[14]
|
Song, K.H., Cha, S., Yu, S.-G., et al. (2013) Association of Apolipoprotein A5 Gene 1131TC Polymorphism with the Risk of Metabolic Syndrome in Korean Subjects. BioMed Research International, 2013, Article ID: 585134.
https://doi.org/10.1155/2013/585134
|
[15]
|
Bogari, N.M., Aljohani, A., Amin, A.A., et al. (2019) A Genetic Variant c.553G > T (rs2075291) in the Apolipoprotein A5 Gene Is Associated with Altered Triglycerides Levels in Coronary Artery Disease (CAD) Patients with Lipid Lowering Drug. BMC Cardiovascular Disorders, 19, Article No. 2. https://doi.org/10.1186/s12872-018-0965-3
|
[16]
|
Abd El-Aziz, T.A. and Mohamed, R.H. (2016) LDLR, ApoB and ApoE Genes Polymorphisms and Classical Risk Factors in Premature Coronary Artery Disease. Gene, 590, 263-269. https://doi.org/10.1016/j.gene.2016.05.032
|
[17]
|
Chen, Y., Lin, M., Liang, Y., et al. (2016) Association between Apolipoprotein B XbaI Polymorphism and Coronary Heart Disease in Han Chinese Population: A Meta-Analysis. Genetic Testing and Molecular Biomarkers, 20, 304-311.
https://doi.org/10.1089/gtmb.2015.0126
|
[18]
|
Afroze, D., Yousuf, A., Tramboo, N., et al. (2016) ApoE Gene Polymorphism and Its Relationship with Coronary Artery Disease in Ethnic Kashmiri Population. Clinical and Experimental Medicine, 16, 551-556.
https://doi.org/10.1007/s10238-015-0389-7
|
[19]
|
Lv, P., Zheng, Y., Huang, J., et al. (2020) Apolipoprotein E Association of Gene Polymorphism with Ischemic Stroke in Coronary Heart Disease Patients Treated with Medium-Intensity Statins. Neuropsychiatric Disease and Treatment, 16, 2459-2466. https://doi.org/10.2147/NDT.S265194
|
[20]
|
Yousuf, F. and Iqbal, M. (2015) Review: Apolipoprotein E (Apo E) Gene Polymorphism and Coronary Heart Disease in Asian Populations. Pakistan Journal of Pharmaceutical Sciences, 28, 1439-1444.
|
[21]
|
Luo, Z., Pu, L., Muhammad, I., et al. (2018) Associations of the PON1 rs662 Polymorphism with Circulating Oxidized Low-Density Lipoprotein and Lipid Levels: A Systematic Review and Meta-Analysis. Lipids in Health and Disease, 17, Article No. 281. https://doi.org/10.1186/s12944-018-0937-8
|
[22]
|
Deng, Z., Xiang, H. and Gao, W. (2020) Significant Association between Paraoxonase1 rs662 Polymorphism and Coronary Heart Disease: A Meta-Analysis in the Chinese Population. Herz, 45, 347-355.
https://doi.org/10.1007/s00059-018-4737-8
|
[23]
|
Chistiakov, D., Melnichenko, A., Orekhov, A., et al. (2017) Paraoxonase and Atherosclerosis-Related Cardiovascular Diseases. Biochimie, 132, 19-27. https://doi.org/10.1016/j.biochi.2016.10.010
|
[24]
|
González-Castro, T.B., Tovilla-Zárate, C.A., Juárez-Rojop, I.E., et al. (2018) PON2 and PPARG Polymorphisms as Biomarkers of Risk for Coronary Heart Disease. Biomarkers in Medicine, 12, 287-297.
https://doi.org/10.2217/bmm-2017-0227
|
[25]
|
Zhang, C., Peng, W., Wang, M., et al. (2010) Studies on Protective Effects of Human Paraoxonases 1 and 3 on Atherosclerosis in Apolipoprotein E Knockout Mice. Gene Therapy, 17, 626-633. https://doi.org/10.1038/gt.2010.11
|
[26]
|
Li, Y., Zhu, J. and Ding, J.Q. (2015) VKORC1 rs2359612 and rs9923231 Polymorphisms Correlate with High Risks of Cardiovascular and Cerebrovascular Diseases. Genetics and Molecular Research, 14, 14731-14744.
https://doi.org/10.4238/2015.November.18.38
|
[27]
|
Du, J., Zhang, Z., Ge, Y., et al. (2015) VKORC1 and CD-14 Genetic Polymorphisms Associate with Susceptibility to Cardiovascular and Cerebrovascular Diseases. International Journal of Clinical and Experimental Medicine, 8, 20444-20453.
|
[28]
|
Turgut Cosan, D., Yazıcı, H., Colak, E., et al. (2017) Susceptiveness of Vitamin K epOxide Reductase Complex Subunit 1 Gene Polymorphism in Essential Hypertension. Genetic Testing and Molecular Biomarkers, 21, 292-297.
https://doi.org/10.1089/gtmb.2016.0311
|
[29]
|
张艳娇, 杨雪婷, 李烨, 等. 云南地区冠心病患者CYP2C19基因多态性分布研究[J]. 中国医院药学杂志, 2021, 41(1): 42-45.
|
[30]
|
Huang, B., Cui, D., Ren, Y., et al. (2017) Effect of Cytochrome P450 2C19*17 Allelic Variant on Cardiovascular and Cerebrovascular Outcomes in Clopidogrel-Treated Patients: A Systematic Review and Meta-Analysis. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 22, 109.
https://doi.org/10.4103/jrms.JRMS_590_16
|
[31]
|
Claassens, D.M.F., Vos, G.J.A., Bergmeijer, T.O., et al. (2019) A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. The New England Journal of Medicine, 381, 1621-1631. https://doi.org/10.1056/NEJMoa1907096
|
[32]
|
Zhang, Y., Zhou, X., Ji, W., et al. (2019) Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease. Current Medical Science, 39, 44-51. https://doi.org/10.1007/s11596-019-1998-2
|
[33]
|
Hou, X., Han, W., Gan, Q., et al. (2018) CYP2C19 and ABCB1 Genetic Polymorphisms Correlate with the Recurrence of Ischemic Cardiovascular Adverse Events after Clopidogrel Treatment. Journal of Clinical Laboratory Analysis, 32, e22369. https://doi.org/10.1002/jcla.22369
|
[34]
|
Sibbing, D., Aradi, D., Alexopoulos, D., et al. (2019) Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 12, 1521-1537. https://doi.org/10.1016/j.jcin.2019.07.011
|
[35]
|
Wang, Y., Du, X., Zhao, R., et al. (2021) Association of APOE Polymorphisms with Lipid-Lowering Efficacy of Statins in Atherosclerotic Cardiovascular Diseases. Annals—Academy of Medicine Singapore, 50, 474-480.
https://doi.org/10.47102/annals-acadmedsg.2020505
|
[36]
|
Jabr, R., Gharaibeh, M., Zayed, A., et al. (2021) The Association between Apolipoprotein E Polymorphism and Response to Statins in Group of Hyperlipidemic Patients. Endocrine, Metabolic &Immune Disorders Drug Targets, 21, 720-725. https://doi.org/10.2174/1871530320666200705211656
|
[37]
|
范春煜, 苏昊, 付强, 等. 他汀类药物代谢相关ApoE基因多态性与冠状动脉介入术后再狭窄的相关性研究[J]. 中国循证心血管医学杂志, 2020, 12(6): 703-707.
|
[38]
|
Zubiaur, P., Benedicto, M., Villapalos-García, G., et al. (2021) SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Journal of Personalized Medicine, 11, 204.
https://doi.org/10.3390/jpm11030204
|
[39]
|
Zhang, D., Ding, Y., Wang, X., et al. (2020) Effects of ABCG2 and SLCO1B1 Gene Variants on Inflammation Markers in Patients with Hypercholesterolemia and Diabetes Mellitus Treated with Rosuvastatin. European Journal of Clinical Pharmacology, 76, 939-946. https://doi.org/10.1007/s00228-020-02882-4
|
[40]
|
Lu, B., Sun, L., Seraydarian, M., et al. (2021) Effect of SLCO1B1 T521C on Statin-Related Myotoxicity with Use of Lovastatin and Atorvastatin. Clinical Pharmacology and Therapeutics, 110, 733-740. https://doi.org/10.1002/cpt.2337
|